Market Research Logo

GlaxoSmithKline Plc - Product Pipeline Review - 2016

GlaxoSmithKline Plc - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘GlaxoSmithKline Plc - Product Pipeline Review - 2016’, provides an overview of the GlaxoSmithKline Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GlaxoSmithKline Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of GlaxoSmithKline Plc
The report provides overview of GlaxoSmithKline Plc including its business description, key facts, and locations and subsidiaries
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report assesses GlaxoSmithKline Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report features GlaxoSmithKline Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate GlaxoSmithKline Plc’s strategic position with total access to detailed information on its product pipeline
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for GlaxoSmithKline Plc
Identify potential new clients or partners in the target demographic
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding GlaxoSmithKline Plc’s pipeline depth and focus of pipeline therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
List of Tables
List of Figures
GlaxoSmithKline Plc Snapshot
GlaxoSmithKline Plc Overview
Key Information
Key Facts
GlaxoSmithKline Plc - Research and Development Overview
Key Therapeutic Areas
GlaxoSmithKline Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
GlaxoSmithKline Plc - Pipeline Products Glance
GlaxoSmithKline Plc - Late Stage Pipeline Products
GlaxoSmithKline Plc - Clinical Stage Pipeline Products
GlaxoSmithKline Plc - Early Stage Pipeline Products
GlaxoSmithKline Plc - Unknown Stage Pipeline Products
GlaxoSmithKline Plc - Drug Profiles
gepirone hydrochloride ER
GSK-257049
GSK-2696273
mepolizumab
melanoma lysate vaccine
(fluticasone furoate + umeclidinium bromide + vilanterol trifenatate)
(fluticasone furoate + vilanterol trifenatate)
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine
albiglutide
ambrisentan
AS15 + recMAGE-A3
belimumab
bupropion hydrochloride ER
Ebola [Zaire] vaccine
fluticasone furoate
GSK-1437173A
inotersen sodium
KD-295
losmapimod
meningococcal [serotype B] vaccine
retosiban
tafenoquine succinate
vilanterol trifenatate
zanamivir
(batefenterol succinate + fluticasone furoate)
(fluticasone furoate + levocabastine hydrochloride)
alitretinoin
batefenterol
CAD-106
camicinal
dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide
danirixin
daprodustat
fluticasone furoate + umeclidinium bromide
gepotidacin mesylate
group B Streptococcus (trivalent) vaccine
GSK-2189242A
GSK-2231392A
GSK-2245035
GSK-2256098
GSK-2269557
GSK-2302032A
GSK-2315698 + GSK-2398852
GSK-2330672
GSK-2339345
GSK-239512
GSK-2586881
GSK-2696274
GSK-2696275
GSK-2789869A
GSK-2830930A
GSK-2838504A
GSK-2862277
GSK-3003891A
GSK-3196165
GSK-3277511A
GSK-692342
GSK-933776
GVXNSD-133
hepatitis C vaccine 1
malaria vaccine
mapatumumab
maribavir
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine
otelixizumab
respiratory syncytial virus vaccine
rilapladib
Streptococcal pneumonia vaccine 3
umeclidinium bromide
GSK-2302025A
GSK-2636771
GSK-525762
HIV [strains C1086 + TV1] (bivalent) vaccine
pazopanib hydrochloride + pembrolizumab
TDEN-PIV
(amlodipine besylate + rosuvastatin calcium)
(candesartan cilexetil + hydrochlorothiazide)
(diphtheria + pertussis (acellular) + tetanus) vaccine
1790GAHB
EcoXyn-4V
epelsiban besylate
FP-1039
GSK-1940029
GSK-2130579A
GSK-2241658A
GSK-2256294
GSK-2330811
GSK-2618960
GSK-2646264
GSK-2654909A
GSK-2654911A
GSK-2789868A
GSK-2798745
GSK-2800528
GSK-2816126
GSK-2831781
GSK-2849330
GSK-2857916
GSK-2878175
GSK-2879552
GSK-2881078
GSK-2981278
GSK-2981710
GSK-2982772
GSK-3008348
GSK-3117391
GSK-3174998
GSK-3206640A
GSK-3206641A
GSK-3389245A
hepatitis C vaccine 2
HIV vaccine 1
HIV vaccine 5
IMP-731
influenza [strain A/H5N1] vaccine
influenza vaccine 2
montelukast sodium
omipalisib
oxytocin
RSV-001
Staphylococcus aureus vaccine
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine
BLyS-gel
Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis
Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa
GSK-030
GSK-1795091
GSK-2041706
GSK-214096
GSK-2225745
GSK-2394002
GSK-2656157
GSK-2795039
GSK-2820151
GSK-3039294
GSK-3277509A
GSK-3277510A
GSK-3326595
GSK-3359609
GSK-6288B
GSK-8853
GSKJ-4
GW-610742
HIV vaccine 2
influenza vaccine
marburg vaccine
meningococcal vaccine 2
Monoclonal Antibody Conjugate for Oncology
raxibacumab
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis
Small Molecule 1 for Malaria
Small Molecule 1 to Inhibit Histone Methyltransferases for Cancer
Small Molecule 2 for Malaria
Small Molecule 2 for Tuberculosis
Small Molecule 2 to Inhibit Histone Methyltransferases for Cancer
Small Molecule 3 to Inhibit Histone Methyltransferases for Cancer
Small Molecule for Hypertension and Insulin Resistance
Small Molecule to Activate AMPK for Type 2 Diabetes
Small Molecule to Agonize S1P1 for Multiple Sclerosis
Small Molecules to Inhibit InhA for Tuberculosis
Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis
staphylococci aureus vaccine
Streptococcal pneumonia vaccine
TC-2153
tuberculosis vaccine
Vaccine for Alzheimer's Disease
Vaccine for Cancer
bacterial vaccine
bacterial vaccine 2
Drug for Chronic Liver Disease
Drugs to Antagonize T-Cell Receptor for Oncology
Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis
GSK-137647A
GSK-343
GSK-5959
GSKJ-1
Proteins for Musculoskeletal Disorders
Pseudomonas aeruginosa vaccine
Small Molecule for Tuberculosis
Small Molecule to Antagonize FFA4 for Undisclosed Indication
Small Molecule to Inhibit Histone Deacetylases for Oncology
Small Molecules for HIV-1 Infection
Small Molecules for Tuberculosis
Small Molecules for Undisclosed Indication
Small Molecules to Antagonize Folate Receptor for Tuberculosis
Small Molecules to Inhibit ATPase family AAA Domain-Containing Protein 2 for Oncology
Small Molecules to Inhibit Falcipain for Malaria
Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis
Small Molecules to Inhibit RNA Polymerase for Hepatitis C
(paratyphoid + typhoid) vaccine
GlaxoSmithKline Plc - Pipeline Analysis
GlaxoSmithKline Plc - Pipeline Products by Target
GlaxoSmithKline Plc - Pipeline Products by Route of Administration
GlaxoSmithKline Plc - Pipeline Products by Molecule Type
GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action
GlaxoSmithKline Plc - Recent Pipeline Updates
GlaxoSmithKline Plc - Dormant Projects
GlaxoSmithKline Plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
GlaxoSmithKline Plc - Company Statement
GlaxoSmithKline Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
GlaxoSmithKline Plc - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 3
List of Tables
GlaxoSmithKline Plc, Key Information
GlaxoSmithKline Plc, Key Facts
GlaxoSmithKline Plc - Pipeline by Indication, 2016
GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016
GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016
GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016
GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016
GlaxoSmithKline Plc - Partnered Products/ Combination Treatment Modalities, 2016
GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016
GlaxoSmithKline Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016
GlaxoSmithKline Plc - Pre-Registration, 2016
GlaxoSmithKline Plc - Filing rejected/Withdrawn, 2016
GlaxoSmithKline Plc - Phase III, 2016
GlaxoSmithKline Plc - Phase II, 2016
GlaxoSmithKline Plc - Phase I, 2016
GlaxoSmithKline Plc - IND/CTA Filed, 2016
GlaxoSmithKline Plc - Preclinical, 2016
GlaxoSmithKline Plc - Discovery, 2016
GlaxoSmithKline Plc - Unknown, 2016
GlaxoSmithKline Plc - Pipeline by Target, 2016
GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016
GlaxoSmithKline Plc - Pipeline by Molecule Type, 2016
GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action, 2016
GlaxoSmithKline Plc - Recent Pipeline Updates, 2016
GlaxoSmithKline Plc - Dormant Developmental Projects,2016
GlaxoSmithKline Plc - Discontinued Pipeline Products, 2016
GlaxoSmithKline Plc, Other Locations
GlaxoSmithKline Plc, Subsidiaries
GlaxoSmithKline Plc, Key Manufacturing Facilities
List of Figures
GlaxoSmithKline Plc - Pipeline by Top 10 Indication, 2016
GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016
GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016
GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016
GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016
GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016
GlaxoSmithKline Plc - Pipeline by Top 10 Target, 2016
GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016
GlaxoSmithKline Plc - Pipeline by Top 10 Molecule Type, 2016
GlaxoSmithKline Plc - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report